Free tool
FAERS Monitor: Dhivy
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 214869 or its brand name (Dhivy, Carbidopa, Levodopa). Reports on generic versions are filed under their own applications.
Reports
3,539
Serious
2,105
59% of reports
Hospitalization
1,034
Death reported
566
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- hallucination479
- fall436
- death370
- drug ineffective354
- confusional state217
- product dose omission issue211
- dizziness202
- fatigue199
- parkinson^s disease195
- gait disturbance175
- nausea172
- tremor170
- asthenia167
- condition aggravated160
- urinary tract infection159
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 4 |
| 2005 | 4 |
| 2011 | 1 |
| 2012 | 14 |
| 2013 | 33 |
| 2014 | 49 |
| 2015 | 82 |
| 2016 | 103 |
| 2017 | 170 |
| 2018 | 284 |
| 2019 | 315 |
| 2020 | 430 |
| 2021 | 290 |
| 2022 | 116 |
| 2023 | 470 |
| 2024 | 638 |
| 2025 | 530 |
| 2026 | 6 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,620 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hallucinationSignal | 479 | 38.0 | 35.0 | 17,176 |
| confusional stateSignal | 217 | 8.0 | 7.0 | 1,329 |
| fallSignal | 436 | 7.8 | 7.1 | 2,614 |
| tremorSignal | 170 | 6.1 | 5.3 | 724 |
| urinary tract infectionSignal | 159 | 5.5 | 4.8 | 592 |
| gait disturbanceSignal | 175 | 5.4 | 4.7 | 635 |
| product dose omission issueSignal | 211 | 4.3 | 3.7 | 532 |
| condition aggravatedSignal | 160 | 3.1 | 2.7 | 233 |
| astheniaSignal | 167 | 2.6 | 2.3 | 172 |
| deathSignal | 370 | 2.6 | 2.3 | 363 |
| dizzinessSignal | 202 | 2.4 | 2.1 | 169 |
| drug ineffective | 354 | 1.6 | 1.4 | 84 |
| fatigue | 199 | 1.5 | 1.3 | 36 |
| nausea | 172 | 1.3 | 1.1 | 11 |
| parkinson^s disease | 195 | 0.0 | 0.0 | 1,153,965 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.